<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Markerless tumor tracking for lung SBRT with the Radixact Synchrony system: Initial experience and short-term clinical outcomes

dc.contributor.authorGoksel, Evren Ozan
dc.contributor.authorOzen, Zeynep
dc.contributor.authorGunduz, Seckin
dc.contributor.authorTure, Artunc
dc.contributor.authorKucucuk, Halil
dc.contributor.authorArifoglu, Alptekin
dc.contributor.authorTezcanli, Evrim
dc.contributor.authorAbacioglu, Ufuk
dc.contributor.authorSengoz, Meric
dc.date.accessioned2026-11-05T11:02:26Z
dc.date.issued2025
dc.description.abstractPurpose To report the initial clinical experience with the radixact synchrony lung with respiratory (LWR) technique in stereotactic body radiotherapy (SBRT) for lung tumors, focusing on feasibility, dosimetric performance, and early clinical outcomes using both standard and extended fractionation regimens. Methods Twenty patients with primary or metastatic lung tumors were treated using the Synchrony LWR technique. Patients were selected based on respiratory stability and favorable imaging characteristics. All patients underwent a Synchrony simulation, which included tumor tracking volume (TTV) definition and kV radiograph acquisition to assess their suitability for treatment with this technique. Treatment plans were generated using Precision TPS with VoloUltra. Plan verification, including gamma analysis and point dose measurements, was performed using the PTW Octavius system and dynamic motion QA. Synchrony model parameters, treatment times, and intrafraction interruptions were analyzed. Clinical follow-up included imaging and toxicity assessment. Results Treatment was successfully delivered in all patients with median beam-on and treatment durations of 9.1 and 14.5 min, respectively. The median number of intrafraction interruptions was 1.95, and none of the fractions were canceled due to prolonged delivery. The mean kV imaging dose per fraction was 0.90 cGy. Dosimetric QA under motion showed gamma passing rates >93% and < 2% deviation in point dose. At a median follow-up of 9 months, the local control rate was 100%, with no grade >= 2 toxicities observed. Conclusions The Radixact Synchrony LWR technique enables efficient and non-invasive respiratory motion management in lung SBRT. This early experience demonstrates its feasibility with clinically acceptable delivery accuracy and promising short-term clinical outcomes.
dc.description.issue12
dc.description.pagese70362
dc.description.volume26
dc.identifier.doi10.1002/acm2.70362
dc.identifier.issn1526-9914
dc.identifier.urihttps://doi.org/10.1002/acm2.70362
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/10915
dc.identifier.wosWOS:001620971700001
dc.language.isoen
dc.publisherWILEY
dc.relation.hasversion10.1002/acm2.70362
dc.relation.ispartofJOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
dc.subjectlung SBRT
dc.subjectmarkerless tumor tracking
dc.subjectmotion management
dc.subjectradixact synchrony
dc.subjectSTEREOTACTIC ABLATIVE RADIOTHERAPY
dc.subjectBODY RADIATION-THERAPY
dc.subjectRESIDUAL MOTION
dc.subjectGATED RADIOTHERAPY
dc.subjectMANAGEMENT
dc.subjectCANCER
dc.subjectTIME
dc.subjectRadiology, Nuclear Medicine & Medical Imaging
dc.titleMarkerless tumor tracking for lung SBRT with the Radixact Synchrony system: Initial experience and short-term clinical outcomes
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.issue12
oaire.citation.volume26
person.identifier.orcid0000-0002-0674-1016
person.identifier.orcid0000-0002-8723-885X

Files

Collections